Trial Profile

A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glenzocimab (Primary)
Indications SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms GARDEN
Sponsors Acticor Biotech

Most Recent Events

15 Nov 2021 Preliminary clinical data (as of May 31, 2021; n=50) assessing safety and efficacy of glenzocimab in patients with COVID-19 related ARDS presented at the American Heart Association Scientific Sessions 2021
10 Sep 2021 Status changed from active, no longer recruiting to completed.
04 Sep 2021 This trial has been completed in France, as per European Clinical Trials Database record. (2021-08-06)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com